{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":40,"sponsored":0,"items":[{"id":"n_ontprppkrslw46rufirq","seq":1552146,"kind":"article","title":"FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL","url":"https://www.finanzen.ch/nachrichten/aktien/fda-approves-expanded-use-of-lillys-jaypirca-for-cll-sll-1036595289","published":"2026-10-03T15:22:11Z","seen":"2026-10-03T15:22:11Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_hf3mdogwmaxv4iik4weq","category":"health","category_p":0.6,"sentiment":"positive","tone":-0.14,"political":0.08},{"id":"n_grhrrjfvhoulttjgre3a","seq":1469348,"kind":"article","title":"Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Counted","url":"https://www.medicaldaily.com/foundayo-orforglipron-predicted-diabetes-risk-attain-1-modeling-479452","summary":"A Lilly-funded modeling analysis tied Foundayo to a 57% lower predicted 10-year diabetes risk. No actual diabetes cases were counted in the study.","published":"2026-10-03T02:30:45Z","seen":"2026-10-03T03:27:25Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"mentions":2,"story":"st_grhrrjfvhoulttjgre3a","category":"health","category_p":0.67,"sentiment":"positive","tone":0.33,"political":0.04},{"id":"n_hqeucdtjxuivvmncj2dq","seq":1451116,"kind":"article","title":"혈액암 첫 치료부터 '제이피르카'…릴리, 美 적응증 확대","title_en":"Blood cancer first treatment with 'Jypnirka'... Lilly expands US approval","url":"https://www.medipana.com/news/articleView.html?idxno=418715","summary":"빅파마 일라이릴리의 혈액암 치료제 \\'제이피르카(성분명 피르토브루티닙)\\'가 미국에서 만성림프구성백혈병(CLL)과 소림프구성림프종(SLL)의 1차 치료 영역까지 진입했다. 기존 공유결합 BTK 억제제 치료 이후 사용되던 비공유결합 BTK 억제제가 치료 경험이 없는 환자로 영역을 넓혔다는 점에서 CLL/SLL 치료 전략의 변화가 주목된다. 미국 식품의약국(FDA)은 2일(현지시간) 제이피르카를 이전 치료 경험이 없고 알려진 17p 결실(del17p)이 없는 성인 CLL/SLL 환자의 치료제로 확대 승인했다. 이에 따라 제이피르카는 미국에","published":"2026-10-02T23:11:26Z","seen":"2026-10-02T23:59:22Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_hqeucdtjxuivvmncj2dq","category":"health","category_p":0.9,"sentiment":"positive","tone":0.39,"political":0.03},{"id":"n_36sdfn3npglkhruic4oa","seq":1439954,"kind":"article","title":"Lilly's Ebglyss Cleared or Nearly Cleared Hand and Foot Eczema in 53% of Patients Versus 27% on Placebo","url":"https://www.medicaldaily.com/ebglyss-hand-foot-eczema-adtouch-trial-479435","published":"2026-10-02T20:10:00Z","seen":"2026-10-02T22:17:26Z","lang":"en","source":{"id":"medicaldaily.com","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics","education"],"authors":["Dorothy Brooks"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"mentions":3,"story":"st_36sdfn3npglkhruic4oa","category":"health","category_p":0.86,"sentiment":"neutral","tone":-0.18,"political":0.01},{"id":"n_ep77polfk6bbuteyhswa","seq":1419182,"kind":"article","title":"Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL","url":"http://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-us-fda-for-certain-patients-with-previously-untreated-cllsll-302897416.html","published":"2026-10-02T19:30:00Z","seen":"2026-10-02T19:47:13Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health","science","education"],"authors":["Eli Lilly","Company"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_ep77polfk6bbuteyhswa","category":"health","category_p":0.67,"sentiment":"neutral","tone":-0.48,"political":0.13},{"id":"n_36ogvpfxkeyscrqou4nq","seq":1386639,"kind":"article","title":"Lilly, Foghorn part ways; Wave's FDA-approved plans","url":"https://www.biopharmadive.com/news/foghorn-eli-lilly-wave-samsung-bioepis-teva-varda-hatteras/831918","published":"2026-10-02T16:25:34Z","seen":"2026-10-02T16:25:34Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["science","economy","business","security"],"authors":["Gwendolyn Wu"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q1320847","name":"foghorn","type":"org"},{"id":"Q262304","name":"Wave","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_36ogvpfxkeyscrqou4nq","category":"arts-culture-entertainment","category_p":0.24,"sentiment":"neutral","tone":0.07,"political":0.06},{"id":"n_a5w453lqkiddgowgw4oq","seq":1379609,"kind":"article","title":"Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ)","url":"https://seekingalpha.com/news/4649834-foghorn-downgraded-td-cowen-lilly-exit","published":"2026-10-02T14:08:00Z","seen":"2026-10-02T15:36:52Z","lang":"en","source":{"id":"seekingalpha.com","name":"seekingalpha.com","domain":"seekingalpha.com","outlet":{"wikidata":"Q3477676","name":"Seeking Alpha","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q1320847","name":"foghorn","type":"org"},{"id":"Q16952393","name":"TD Cowen","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q104481160","name":"Foghorn Therapeutics (United States)","type":"other"},{"id":"Q82059","name":"Nasdaq","type":"org"}],"story":"st_l4sstps4bhkcxry5o4bq","category":"economy-business","category_p":0.64,"sentiment":"neutral","tone":-0.16,"political":0.06},{"id":"n_ovyyjlkrp3pvly4yb23a","seq":1360877,"kind":"article","title":"STAT+: Lilly bypasses Australian pharmacies with DTC model","url":"https://www.statnews.com/2026/10/02/biotech-news-lilly-bypasses-australian-phramacies-with-dtc-model","summary":"Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.","published":"2026-10-02T13:58:31Z","seen":"2026-10-02T14:08:27Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-aa5345","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-aa5345","topics":["healthcare","usa","medicine","biotech","business","pharma","the readout","biotechnology"],"authors":["Meghana Keshavan"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"image":"https://www.statnews.com/wp-content/uploads/2024/08/s3___bgmp-arc_arc-feeds_generic-photos_to-arc_greenhouse14LillySeaport1-645x645.jpg","mentions":3,"story":"st_ovyyjlkrp3pvly4yb23a","category":"economy-business","category_p":0.75,"sentiment":"neutral","tone":0.09,"political":0.3},{"id":"n_ta75lukeem3k5tcvc4sq","seq":1266837,"kind":"article","title":"Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 Diabetes","url":"https://www.medicaldaily.com/eloralintide-tirzepatide-eloratzp-phase-2-type-2-diabetes-easd-2026-479396","summary":"Lilly's eloralintide plus tirzepatide produced 23.3% weight loss vs 14.8% for tirzepatide alone in a Phase 2 diabetes trial. Here's the catch.","published":"2026-10-02T03:51:58Z","seen":"2026-10-02T04:54:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"mentions":2,"story":"st_zxnkx3qznzoozw6wvhta","category":"health","category_p":0.77,"sentiment":"positive","tone":0.48,"political":0.01},{"id":"n_o2nxmki3byikpybshhwa","seq":1266846,"kind":"article","title":"Lilly's Foundayo Pill Matched Insulin on Heart Safety in Lancet Trial, but Its Lower Death Rate Needs Caution","url":"https://www.medicaldaily.com/foundayo-orforglipron-achieve-4-lancet-heart-safety-insulin-479387","summary":"Lilly's Foundayo pill met a heart-safety test against insulin in a Lancet trial. Fewer deaths were seen, but that result is secondary.","published":"2026-10-02T03:22:18Z","seen":"2026-10-02T04:54:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q120491908","name":"orforglipron","type":"other"}],"mentions":2,"story":"st_o2nxmki3byikpybshhwa","category":"health","category_p":0.7,"sentiment":"neutral","tone":0.04,"political":0.01},{"id":"n_4rfzvmu6iib5igniobtq","seq":1244210,"kind":"article","title":"India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO","url":"https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-has-biotech-talent-and-know-how-but-funding-ecosystem-lags-lilly-ceo/articleshow/134626945.cms","published":"2026-10-02T00:45:00Z","seen":"2026-10-02T01:31:11Z","lang":"en","source":{"id":"indiatimes.com","name":"indiatimes.com","domain":"indiatimes.com","outlet":{"wikidata":"Q113974698","name":"Indiatimes","type":"other","country":"IN","designations":["news media"]}},"via":"gdelt-gkg-english","topics":["economy","science","security","politics"],"authors":["Vikas Dandekar"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_4rfzvmu6iib5igniobtq","category":"economy-business","category_p":0.83,"sentiment":"positive","tone":0.5,"political":0.04},{"id":"n_4ii6je2bewyqxccvenwa","seq":1240262,"kind":"article","title":"릴리와 손잡아도 신약은 어렵다…포그혼, 개발 중단에 40% 감원","title_en":"Even with Lilly, a new drug is difficult... Foghorn, development halted, 40% layoffs","url":"https://www.medipana.com/news/articleView.html?idxno=418647","summary":"포그혼 테라퓨틱스가 일라이 릴리와 공동개발하던 항암제 프로그램을 중단하고 직원 약 40%를 감축한다. 임상 1상 자료를 검토한 뒤 후속 개발을 확대하지 않기로 결정하면서, 자체 보유 후보물질에 자원을 집중하는 방향으로 연구개발 전략을 재편한다. 미국 바이오기업 포그혼 테라퓨틱스(Foghorn Therapeutics)는 1일(현지시간) 빅파마 릴리와 함께 개발 중인 \\'FHD-909(LY4050784)\\'를 임상 개발 확대 단계로 진행하지 않기로 했다고 밝혔다. 이번 결정은 임상 1상 용량증량 시험에서 확보한 자료를 검토한 결과다. 양사","published":"2026-10-01T23:48:36Z","seen":"2026-10-02T00:25:40Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q1320847","name":"foghorn","type":"org"}],"story":"st_4ii6je2bewyqxccvenwa","category":"economy-business","category_p":0.52,"category2":"health","sentiment":"negative","tone":-0.39,"political":0.09},{"id":"n_6rqvodz545kep4kwdxiq","seq":1242868,"kind":"article","title":"The Oval Series Finale: Why Lilly and Bobby Get One of the Show’s Few Happy Endings","url":"https://www.macobserver.com/entertainment/the-oval-series-finale-why-lilly-and-bobby-get-one-of-the-shows-few-happy-endings","summary":"Lilly and Bobby escape with fake identities and leave together. In a finale filled with shootings, poison and unresolved explosions, their shared exit is one of the rare outcomes presented as hopeful. The central point is not only what happens, but why it changes the characters who remain. The confirmed details below separate the onscreen […] The post The Oval Series Finale: Why Lilly and Bobby Get One of the Show’s Few Happy Endings appeared first on The Mac Observer .","published":"2026-10-01T22:35:00Z","seen":"2026-10-02T01:09:08Z","lang":"en","source":{"id":"kite-macobserver-com-f8d979","name":"macobserver.com","domain":"macobserver.com","outlet":{"wikidata":"Q130217201","name":"the MacObserver","type":"magazine","designations":["online magazine"]}},"via":"kite-macobserver-com-f8d979","topics":["apple","entertainment","bet","the oval"],"authors":["Shane Watson"],"entities":[{"id":"Q1073913","name":"Lilly","type":"person"}],"story":"st_6rqvodz545kep4kwdxiq","category":"arts-culture-entertainment","category_p":0.59,"sentiment":"negative","tone":-0.35,"political":0.06},{"id":"n_54ktn4p4ztaqizlnccxq","seq":1227602,"kind":"article","title":"Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial","url":"https://www.raps.org/resource/recon-sanofi-regeneron-expand-partnership-after-dupixent-success-lilly-amylin-zepbound-combo-succeeds-in-mid-stage-trial.html","published":"2026-10-01T19:50:00Z","seen":"2026-10-01T22:23:18Z","lang":"en","source":{"id":"raps.org","name":"raps.org","domain":"raps.org"},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q158205","name":"Sanofi","type":"org"},{"id":"Q97159313","name":"Dupixent","type":"other"},{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q108324770","name":"tirzepatide","type":"other"}],"story":"st_7jv5rchntqf2sr24tvoa","category":"health","category_p":0.47,"sentiment":"positive","tone":0.74,"political":0.03},{"id":"n_dpdppebshkjcobh2iowa","seq":1035325,"kind":"article","title":"Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysis","url":"https://www.medicaldaily.com/foundayo-vs-oral-semaglutide-25mg-indirect-comparison-easd-2026-479315","summary":"Lilly's indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.","published":"2026-10-01T01:24:20Z","seen":"2026-10-01T02:21:05Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_wpesggivik3aor6gkvhq","category":"health","category_p":0.69,"sentiment":"neutral","tone":0.26,"political":0.02},{"id":"n_64dixlc32fz5qefuc4ja","seq":942986,"kind":"article","title":"Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial","url":"https://www.finanzen.ch/nachrichten/aktien/lillys-eloratzp-delivers-weight-loss-results-in-phase-2b-trial-1036586170","published":"2026-09-30T15:42:30Z","seen":"2026-09-30T15:42:30Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_6gukzcnd2mqtg377bpmq","category":"health","category_p":0.58,"sentiment":"positive","tone":-0.36,"political":0.03},{"id":"n_2t7iomuin4vklce7hz4q","seq":935559,"kind":"article","title":"Combinação experimental da Lilly supera Zepbound em estudo para perda de peso","title_en":"Lilly's experimental combination outperforms Zepbound in weight loss study","url":"https://valor.globo.com/empresas/noticia/2026/09/30/combinao-experimental-da-lilly-supera-zepbound-em-estudo-para-perda-de-peso.ghtml","summary":"A Eli Lilly afirmou nesta quarta-feira (30) que seu medicamento experimental combinado para perda de peso superou o Zepbound, seu produto de grande sucesso, em um estudo comparativo direto, intensificando a concorrência com a rival dinamarquesa Novo Nordisk por novas terapias mais eficazes contra a obesidade. A farmacêutica, sediada em Indianápolis, disse que pacientes com diabetes que receberam a maior dose testada de EloraTZP, combinação de tirzepatida com o medicamento…","published":"2026-09-30T15:12:51Z","seen":"2026-09-30T15:18:22Z","lang":"pt","country":"BR","source":{"id":"kite-pox-globo-com-4344ca","name":"pox.globo.com","domain":"pox.globo.com"},"via":"kite-pox-globo-com-4344ca","topics":["valor"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q108324770","name":"tirzepatide","type":"other"}],"image":"https://s2-valor.glbimg.com/V45MM691g9wKg6v_dlOKf5KmDyo=/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2026/x/X/Mn1OZRQsAqxC0vEhLROA/431631884.jpg","story":"st_iuweffe4hn57djcdktwq","category":"health","category_p":0.28,"category2":"lifestyle-leisure","sentiment":"positive","tone":0.33,"political":0.01},{"id":"n_iuweffe4hn57djcdktwq","seq":956628,"kind":"article","title":"Fármaco combinado experimental de Lilly supera a Zepbound en ensayo clínico para perder peso","title_en":"Lilly's experimental combination drug outperforms Zepbound in weight loss clinical trial","url":"https://www.eleconomista.com.mx/internacionales/farmaco-combinado-experimental-lilly-supera-zepbound-ensayo-clinico-perder-peso-20260930-836078.html","summary":"Eli Lilly anunció que su fármaco experimental combinado para la pérdida de peso superó a su superventas Zepbound en un ensayo comparativo directo, lo que intensifica la competencia con Novo Nordisk por nuevas terapias contra la obesidad más eficaces.","published":"2026-09-30T15:00:00Z","seen":"2026-09-30T16:47:15Z","lang":"es","country":"MX","source":{"id":"kite-eleconomista-com-mx-75cf4a","name":"eleconomista.com.mx","domain":"eleconomista.com.mx","outlet":{"wikidata":"Q1324106","name":"El Economista","type":"newspaper","country":"MX","designations":["news website","newspaper"]}},"via":"kite-eleconomista-com-mx-75cf4a","topics":["geopolítica"],"authors":["Reuters"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"image":"https://imagenes.eleconomista.com.mx/files/og_thumbnail/uploads/2023/05/03/66e8314611538.jpeg","story":"st_iuweffe4hn57djcdktwq","category":"health","category_p":0.56,"sentiment":"positive","tone":0.38,"political":0.02},{"id":"n_6uwb4mfyanuhk7j7nlmq","seq":926831,"kind":"article","title":"People With Type 2 Diabetes Lost up to 60 Pounds on Lilly's Latest Weight Loss Drug","url":"https://www.today.com/health/news/people-type-2-diabetes-lost-60-pounds-lillys-latest-weight-loss-drug-rcna600660","published":"2026-09-30T14:41:57Z","seen":"2026-09-30T14:41:57Z","lang":"en","source":{"id":"today.com","name":"today.com","domain":"today.com","outlet":{"wikidata":"Q130838","name":"Today","type":"broadcaster","designations":["live broadcast","news program","news website","television series"]}},"via":"gdelt-gkg-english","topics":["education","economy","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.63,"sentiment":"positive","tone":-0.38,"political":0.01},{"id":"n_wnbj4lomngwrigbwnofq","seq":875336,"kind":"article","title":"Lilly sets up next-gen obesity battle with full phase 3 retatrutide data","url":"https://www.fiercebiotech.com/biotech/eli-lilly-sets-next-gen-obesity-battle-full-phase-3-retatrutide-data","published":"2026-09-30T09:56:40Z","seen":"2026-09-30T09:56:40Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["health","economy","science"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_wnbj4lomngwrigbwnofq","category":"science-technology","category_p":0.38,"category2":"health","sentiment":"positive","tone":0.09,"political":0.03},{"id":"n_m3dfp3czzklcfim4as2q","seq":865654,"kind":"article","title":"Lilly's Retatrutide Drives Significant Weight Loss And A1C Improvement In Phase 3 Diabetes Study","url":"https://www.rttnews.com/3695022/lilly-s-retatrutide-drives-significant-weight-loss-and-a1c-improvement-in-phase-3-diabetes-study.aspx","published":"2026-09-30T05:00:00Z","seen":"2026-09-30T09:13:21Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_ylaa75jcypkkafihkw7q","category":"health","category_p":0.7,"sentiment":"positive","tone":0.26,"political":0.01},{"id":"n_nlolztlr3kyb7wo66naq","seq":794772,"kind":"article","title":"비만·당뇨 약 패권 다툼…노보·릴리 맞불 수치로 자사 우위 주장","title_en":"Obesity and diabetes drug dominance battle... Novo and Lilly argue figures to claim company superiority","url":"https://www.pharmnews.com/news/articleView.html?idxno=306580","summary":"[팜뉴스=우정민 기자] 노보와 일라이 릴리가 자사 치료제의 우위를 다투고 있다. 차세대 비만 및 당뇨병 치료제 시장 주도권을 둘러싸고 양사는 임상 3상 성과와 간접 통계 분석, 대규모 실사용 데이터(RWE)를 각각 발표하며 정면으로 대립했다.각사가 자사 약물의 우수한 체중 감량 효과와 심혈관 혜택을 전면에 강조함에 따라 글로벌 제약 시장의 경쟁 구도가 가열되는 양상이다.노보는 주사제 임상 데이터를 통해 일라이 릴리 치료제 대비 우수한 체중 감량 성과를 제시했다. 임상 REIMAGINE 5 결과에 따르면 카그리세마(CagriSema)","published":"2026-09-30T00:22:19Z","seen":"2026-09-30T00:29:45Z","lang":"ko","source":{"id":"kite-cdn-pharmnews-com-3e2457","name":"cdn.pharmnews.com","domain":"cdn.pharmnews.com"},"via":"kite-cdn-pharmnews-com-3e2457","topics":["medicine","산업"],"authors":["우정민 기자"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_nlolztlr3kyb7wo66naq","category":"economy-business","category_p":0.47,"category2":"health","sentiment":"neutral","tone":-0.19,"political":0.11},{"id":"n_gnifsuydcds4imlu2ozq","seq":817836,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC 5 Dallas-Fort Worth","url":"https://www.nbcdfw.com/news/health/lillys-weight-loss-drug-type-2-diabetes/4084424","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T04:04:17Z","lang":"en","source":{"id":"nbcdfw.com","name":"nbcdfw.com","domain":"nbcdfw.com","outlet":{"wikidata":"Q3191571","name":"KXAS-TV","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.52,"sentiment":"negative","tone":-0.49,"political":0.01},{"id":"n_3jpbst3lly646i4o64tq","seq":817182,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC Connecticut","url":"https://www.nbcconnecticut.com/news/health/lillys-weight-loss-drug-type-2-diabetes/3779881","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T04:04:17Z","lang":"en","source":{"id":"nbcconnecticut.com","name":"nbcconnecticut.com","domain":"nbcconnecticut.com","outlet":{"wikidata":"Q7956853","name":"WVIT","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.58,"sentiment":"negative","tone":-0.55,"political":0.02},{"id":"n_egjht7fdid4yc6nxriiq","seq":815385,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC New York","url":"https://www.nbcnewyork.com/news/health/lillys-weight-loss-drug-type-2-diabetes/6553681","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T03:52:16Z","lang":"en","source":{"id":"nbcnewyork.com","name":"nbcnewyork.com","domain":"nbcnewyork.com","outlet":{"wikidata":"Q2731065","name":"WNBC","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.57,"sentiment":"negative","tone":-0.54,"political":0.02},{"id":"n_uuou5is5on2logk2q3qq","seq":814545,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC Chicago","url":"https://www.nbcchicago.com/news/health/lillys-weight-loss-drug-type-2-diabetes/3995461","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T03:40:44Z","lang":"en","source":{"id":"nbcchicago.com","name":"nbcchicago.com","domain":"nbcchicago.com","outlet":{"wikidata":"Q3564723","name":"WMAQ-TV","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.54,"sentiment":"negative","tone":-0.5,"political":0.01},{"id":"n_4bmatr64fae63lgzhnxa","seq":810830,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC 7 San Diego","url":"https://www.nbcsandiego.com/news/health/lillys-weight-loss-drug-type-2-diabetes/4080277","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T03:21:37Z","lang":"en","source":{"id":"nbcsandiego.com","name":"nbcsandiego.com","domain":"nbcsandiego.com","outlet":{"wikidata":"Q6334551","name":"KNSD","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q3025883","name":"type 2 diabetes","type":"other"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.52,"sentiment":"negative","tone":-0.49,"political":0.02},{"id":"n_2i25ojmol6vgggz4b3na","seq":807728,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC Los Angeles","url":"https://www.nbclosangeles.com/news/national-international/lillys-weight-loss-drug-type-2-diabetes/3948950","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T02:45:26Z","lang":"en","source":{"id":"nbclosangeles.com","name":"nbclosangeles.com","domain":"nbclosangeles.com","outlet":{"wikidata":"Q2382261","name":"KNBC","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.52,"sentiment":"negative","tone":-0.51,"political":0.01},{"id":"n_x3iookhsy7oxwzftdhzq","seq":801815,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC Bay Area","url":"https://www.nbcbayarea.com/news/health/lillys-weight-loss-drug-type-2-diabetes/4150503","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T01:52:14Z","lang":"en","source":{"id":"nbcbayarea.com","name":"nbcbayarea.com","domain":"nbcbayarea.com","outlet":{"wikidata":"Q721688","name":"KNTV","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q721688","name":"KNTV","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.59,"sentiment":"negative","tone":-0.5,"political":0.01},{"id":"n_5fbxqud7umrduuaf2pza","seq":801803,"kind":"article","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug – NBC10 Philadelphia","url":"https://www.nbcphiladelphia.com/news/health/lillys-weight-loss-drug-type-2-diabetes/4471470","published":"2026-09-30T00:03:00Z","seen":"2026-09-30T01:52:14Z","lang":"en","source":{"id":"nbcphiladelphia.com","name":"nbcphiladelphia.com","domain":"nbcphiladelphia.com","outlet":{"wikidata":"Q3564630","name":"WCAU","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_mh2cpq4c2q3jciflaysq","category":"health","category_p":0.55,"sentiment":"negative","tone":-0.53,"political":0.01},{"id":"n_ylaa75jcypkkafihkw7q","seq":782672,"kind":"article","title":"Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes","url":"http://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html","published":"2026-09-29T22:53:13Z","seen":"2026-09-29T22:53:13Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","politics","health","business"],"authors":["Eli Lilly","Company"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q120468350","name":"retatrutide","type":"other"},{"id":"Q12174","name":"obesity","type":"other"},{"id":"Q3025883","name":"type 2 diabetes","type":"other"}],"story":"st_ylaa75jcypkkafihkw7q","category":"health","category_p":0.56,"sentiment":"positive","tone":-0.17,"political":0.01},{"id":"n_btvz2rudw4grqk6xjkcq","seq":673650,"kind":"article","title":"Lilly says Zepbound tops Novo's Wegovy HD (LLY:NYSE)","url":"https://seekingalpha.com/news/4647999-lilly-says-zepbound-tops-novo-wegovy-hd","published":"2026-09-29T12:39:00Z","seen":"2026-09-29T12:57:19Z","lang":"en","source":{"id":"seekingalpha.com","name":"seekingalpha.com","domain":"seekingalpha.com","outlet":{"wikidata":"Q3477676","name":"Seeking Alpha","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_btvz2rudw4grqk6xjkcq","category":"economy-business","category_p":0.33,"category2":"arts-culture-entertainment","sentiment":"neutral","tone":-0.35,"political":0.03},{"id":"n_mjzyx2s4ddunyqzumyqa","seq":648013,"kind":"article","title":"Lilly stikker til Novo: Slår Novos stærkeste middel","title_en":"Lilly surpasses Novo: Beats Novo's strongest drug","url":"https://borsen.dk/nyheder/virksomheder/lilly-stikker-til-novo-slar-novos-staerkeste-middel","summary":"En analyse af forskellige forsøg med Eli Lillys tirzepatid og Novos Wegovy konkluderer, at Eli Lillys vægttabsmiddel er mere effektiv end Novos","published":"2026-09-29T11:01:58Z","seen":"2026-09-29T11:11:34Z","lang":"da","country":"DK","source":{"id":"kite-borsen-dk-ead9a0","name":"borsen.dk","domain":"borsen.dk","outlet":{"wikidata":"Q5208470","name":"Dagbladet Børsen","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper"]}},"via":"kite-borsen-dk-ead9a0","authors":["author"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://media.borsen.dk/brapi/size/1200/d1bbb6ff-463e-4eae-996b-2d2bb0a930bf-landscape/4098318-20260929070948/7a8f189b07c8ff62fe3d26a8cc8994ad4b71ad6f439cec64addff17df62b1382.jpg","story":"st_mjzyx2s4ddunyqzumyqa","category":"health","category_p":0.29,"sentiment":"neutral","tone":-0.09,"political":0.05},{"id":"n_wpesggivik3aor6gkvhq","seq":627542,"kind":"article","title":"Lilly's Foundayo Tops Oral Semaglutide In New Diabetes Analysis","url":"https://www.rttnews.com/3694673/lilly-s-foundayo-tops-oral-semaglutide-in-new-diabetes-analysis.aspx","published":"2026-09-29T08:44:00Z","seen":"2026-09-29T09:25:18Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q120491908","name":"orforglipron","type":"org"},{"id":"Q27261089","name":"semaglutide","type":"other"}],"story":"st_wpesggivik3aor6gkvhq","category":"health","category_p":0.53,"sentiment":"positive","tone":0.02,"political":0.01},{"id":"n_hcn3rip5scpbxu4nycoa","seq":514111,"kind":"article","title":"Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?","url":"https://www.insidermonkey.com/news/novo-nordisk-just-beat-lilly-in-a-trial-is-the-comeback-finally-taking-shape-1845069","published":"2026-09-28T20:08:19Z","seen":"2026-09-28T20:08:19Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Noor Ul Ain Rehman"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_hcn3rip5scpbxu4nycoa","category":"economy-business","category_p":0.46,"sentiment":"positive","tone":0.04,"political":0.02},{"id":"n_bvnbajvtgxlmpuyd4ila","seq":479417,"kind":"article","title":"Empresas.- Lilly impulsa una iniciativa para llevar sus tratamientos para obesidad y diabetes a países de renta baja","title_en":"Lilly pushes an initiative to bring its obesity and diabetes treatments to low-income countries","url":"https://www.infosalus.com/farmacia/noticia-empresas-lilly-impulsa-iniciativa-llevar-tratamientos-obesidad-diabetes-paises-renta-baja-20260928180709.html","summary":"Eli Lilly and Company ha puesto en marcha 'Lilly Change the Course Commitment' ('Compromiso para cambiar el rumbo'), una nueva iniciativa de salud global cuyo objetivo es lograr la paridad en el número de pacientes tratados con los medicamentos innovadores de Lilly para la diabetes y la obesidad.","published":"2026-09-28T16:07:09Z","seen":"2026-09-28T16:58:29Z","lang":"es","source":{"id":"kite-infosalus-com-ae054a","name":"infosalus.com","domain":"infosalus.com"},"via":"kite-infosalus-com-ae054a","topics":["medicine","infosalus.com","farmacia"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"image":"https://img.europapress.es/fotoweb/fotonoticia_20260928180709_120.jpg","story":"st_bvnbajvtgxlmpuyd4ila","category":"economy-business","category_p":0.64,"category2":"health","sentiment":"positive","tone":0.66,"political":0.1},{"id":"n_xct3ztyha5d2iqiusfka","seq":443170,"kind":"article","title":"Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients","url":"https://pmlive.com/pharma_news/lilly-gets-fda-approval-for-severe-alopecia-areata-treatment-for-paediatric-patients","published":"2026-09-28T11:59:00Z","seen":"2026-09-28T14:00:24Z","lang":"en","source":{"id":"pmlive.com","name":"pmlive.com","domain":"pmlive.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_ypvaxu6tdn33oisujf3q","category":"health","category_p":0.76,"sentiment":"positive","tone":-0.18,"political":0.06},{"id":"n_j2xvvg3rx4dbmpo3qcbq","seq":322517,"kind":"article","title":"미 릴리 주 1회 인슐린 승인","title_en":"US approves once-daily insulin by Lilly","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3012826","summary":"[의학신문·일간보사=김자연 기자] 미국에서 일라이 릴리가 주 1회 투여 기저 인슐린 온스위크(Onswik, insulin efsitora alfa-gobe)의 FDA 승인을 받았다고 발표했다.이는 2형 당뇨병 환자에 대해 승인됐고 임상시험 결과 란투스나 트레시바에 비해 비열등성을 보였으며 라벨에 저혈당 경고가 실렸다. 앞서 유럽, 일본, 멕시코에서도 승인된 온스위크는 퀵펜으로 전달되며 500units/mL와 1000units/mL로 이용 가능하다. 이에 비해 최근 미국에서 출시된 노보의 경쟁제품 어위클리(Awiqli, insulin","published":"2026-09-28T00:32:08Z","seen":"2026-09-28T01:37:01Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","해외"],"authors":["김자연 기자"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_j2xvvg3rx4dbmpo3qcbq","category":"health","category_p":0.72,"sentiment":"positive","tone":0.4,"political":0.03},{"id":"n_uk7t5epiw3tnwqyrhawq","seq":317366,"kind":"article","title":"FDA, 12세 이상 청소년 중증 원형 탈모 치료제 릴리 '올루미언트' 승인","title_en":"FDA approves 'Olumiant' by Lilly for the treatment of severe alopecia areata in adolescents aged 12 and over","url":"https://www.pharmnews.com/news/articleView.html?idxno=306527","summary":"[팜뉴스=우정민 기자] FDA가 12세 이상 청소년 중증 원형 탈모증 치료제를 승인했다. 미국 식품의약국(FDA)은 일라이 릴리의 구강 제제 올루미언트(Olumiant, 성분명 바리시티닙/baricitinib)를 12세 이상 소아 및 청소년 중증 원형 탈모 환자용 치료제로 승인했다.이번 결정으로 기존 성인 환자 대상 처방 범위가 청소년 환자군까지 확대 승인됐다. 원형 탈모증은 면역계가 모낭을 공격해 발생하는 자가면역 질환으로, 두피 및 체모의 모발 손실을 동반한다.전체 환자의 약 40%가 20세 이전에 발병하며, 소아·청소년기에 발","published":"2026-09-27T23:51:31Z","seen":"2026-09-28T00:32:49Z","lang":"ko","source":{"id":"kite-cdn-pharmnews-com-3e2457","name":"cdn.pharmnews.com","domain":"cdn.pharmnews.com"},"via":"kite-cdn-pharmnews-com-3e2457","topics":["medicine","산업"],"authors":["우정민 기자"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_uk7t5epiw3tnwqyrhawq","category":"health","category_p":0.49,"sentiment":"positive","tone":0.3,"political":0.06},{"id":"n_ypvaxu6tdn33oisujf3q","seq":271408,"kind":"article","title":"FDA Expands Lilly's Olumiant Approval To Adolescents With Severe Alopecia Areata","url":"https://www.rttnews.com/3694089/fda-expands-lilly-s-olumiant-approval-to-adolescents-with-severe-alopecia-areata.aspx","published":"2026-09-27T13:16:00Z","seen":"2026-09-27T16:22:40Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q5075435","name":"alopecia areata","type":"other"}],"story":"st_ypvaxu6tdn33oisujf3q","category":"health","category_p":0.56,"sentiment":"positive","tone":-0.01,"political":0.06}]}